GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Special Drug Use Investigation for LAMICTAL Bipolar
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1036
- Registration Number
- NCT01428518
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 124
- Registration Number
- NCT01428453
- Locations
- πΈπͺ
GSK Investigational Site, Stockholm, Sweden
Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males
- Conditions
- Influenza, Human
- Interventions
- Drug: GR121167 SolutionDrug: Placebo
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT01428479
- Locations
- π―π΅
GSK Investigational Site, Tokyo, Japan
PET Study to Study Tumour Apoptosis
- Conditions
- Cancer
- Interventions
- Radiation: 18FML10
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7
- Registration Number
- NCT01428440
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
[18F]PBR111 and Microglial Activation in Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Radiation: [18F]PBR111
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT01428505
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT01424462
- Locations
- π¦πΊ
GSK Investigational Site, Randwick, New South Wales, Australia
Intranasal SB-705498 in Allergic Rhinitis (AR) Patients
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT01424397
- Locations
- π¦πΉ
GSK Investigational Site, Vienna, Austria
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
- Conditions
- Hepatitis C
- Interventions
- Drug: GSK2336805 150mgOther: Placebo
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT01424540
- Locations
- πΊπΈ
GSK Investigational Site, Buffalo, New York, United States
NOGO-A in Multiple Sclerosis FTIH
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3
- Registration Number
- NCT01424423
- Locations
- π¦πΊ
GSK Investigational Site, Heidelberg, Victoria, Australia
SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT01424514
- Locations
- π¨π¦
GSK Investigational Site, Mississauga, Ontario, Canada